Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Diabetes and Vascular Disease Research
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Chapman, M J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chapman, M J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Metabolic syndrome and type 2 diabetes: lipid and physiological consequences

M John Chapman

Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Pitié, Paris, France.

The metabolic syndrome and type 2 diabetes are insulin-resistant states which are commonly associated with an atherogenic dyslipidaemia involving mild to moderately elevated triglycerides, a preponderance of small, dense low-density lipoprotein (LDL) particles and low levels of high-density lipoprotein cholesterol (HDL-C). In addition, there is a spectrum of qualitative changes in the lipoprotein profile, particularly in the functional capacity of HDL to facilitate cellular cholesterol efflux and to protect LDL against oxidative modification. Together, these quantitative and qualitative anomalies promote elevated oxidative stress, endothelial dysfunction and inflammation, which drive the development of premature atherosclerotic cardiovascular disease. Moreover, recent evidence indicates that this dyslipidaemic profile may play a critical role in the development and progression of diabetic microvascular disease. An integrated therapeutic approach to correct both the quantitative and qualitative changes characteristic of diabetic dyslipidaemia clearly constitutes a priority for reduction of both macrovascular and microvascular risk.

Key Words: atherosclerosis • dyslipidaemia • lipid metabolism • microvascular disease • type 2 diabetes

Diabetes and Vascular Disease Research, Vol. 4, No. 3 Suppl, S5-S8 (2007)
DOI: 10.3132/dvdr.2007.050
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J. Lipid Res.Home page
L. S. Kumpula, S. M. Makela, V.-P. Makinen, A. Karjalainen, J. M. Liinamaa, K. Kaski, M. J. Savolainen, M. L. Hannuksela, and M. Ala-Korpela
Characterization of metabolic interrelationships and in silico phenotyping of lipoprotein particles using self-organizing maps
J. Lipid Res., February 1, 2010; 51(2): 431 - 439.
[Abstract] [Full Text] [PDF]